健友股份(603707.SH)：三期临床预估于明年第一季度开始

Core Viewpoint - The company Jianyou Co., Ltd. (603707.SH) has announced that the Phase II clinical trial of the XTMAB project has concluded successfully, with plans to initiate Phase III clinical trials in the first quarter of next year [1] Group 1 - The Phase II clinical trial results for the XTMAB project are reported to be positive [1] - The anticipated start date for the Phase III clinical trial is projected for the first quarter of next year [1]